Twist Bioscience Corp 8-K

What Happened

• Twist Bioscience Corp. (TWST) filed an 8-K on February 17, 2026 announcing unregistered sales of its common stock. The company stated the shares will be issued in private transactions and not through a public offering, relying on the Section 4(a)(2) exemption of the Securities Act. The filing notes shares will be issued in the future pursuant to Stock Purchase Agreements.

Key Details

• Filing date: February 17, 2026 (Form 8‑K).
• Exemption used: Section 4(a)(2) of the Securities Act — transactions not involving a public offering.
• Future issuance: Shares to be issued pursuant to Stock Purchase Agreements (specific share counts/prices were not disclosed in the 8‑K).
• Exhibits filed: form of Registration Rights Agreement (Exhibit 4.1) and legal opinion of Orrick, Herrington & Sutcliffe LLP (Exhibit 5.1).

Why It Matters

• The company’s disclosure confirms private share issuances that are currently exempt from registration; when those shares are issued they can dilute existing shareholders’ ownership.
• The inclusion of a Registration Rights Agreement exhibit indicates the company has documented investors’ rights regarding future registration of the shares, and the legal opinion accompanies the private placement filings.
• The filing also contains standard forward‑looking statement language and refers investors to Twist’s risk factors in its Form 10‑K filed November 17, 2025 for additional context on risks and uncertainties.